Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1-and BMP-2-independent manner

被引:21
作者
Izumo, N [1 ]
Fujita, T [1 ]
Nakamuta, H [1 ]
Koida, M [1 ]
机构
[1] Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Hirakata, Osaka 5730101, Japan
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 2001年 / 23卷 / 07期
关键词
bone morphogenetic protein-2 (BMP-2); core binding factor (Cbfa1); osteogenesis; Rho-GTPase; statins;
D O I
10.1358/mf.2001.23.7.662123
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mevastatin (3-10 muM) and fluvastatin (0.1-10 muM), but not pravastatin, were found to promote calcification of MC3T3-E1 cells and their subclone MC4, in either the presence or absence of 3 mM inorganic phosphate stimulus. The mechanism of action was examined. Gel retardation assay and immunocytochemical analysis of core binding factor (Cbfa1) revealed that mevastatin and fluvastatin completed the nuclear export of Cbfa1, possibly thereby reducing the induction of the stably transfected p60SE2-luc gene, and then promoted Cbfa1-independent calcification, which invariably occurred in both wild type and dominant negative Cbfa1-expressing cells. The induction of the bone morphogenetic protein-2 (BMP-2) gene promoter failed to respond to the statins. All the effects of the cell-permeable statins were negated by mevalonate pathway metabolites (geranylgeranylpyrophosphate > farnesylpyrophosphate > mevalonate) and reproduced by toxin B (a Rho-specific inhibitor), but not totally by Y27632 (a ROCK-specific inhibitor). The results suggest that lipophilic statins can be osteogenic by promoting Cbfa1- and BMP-2-independent calcification processes. (C) 2001 Prous Science. All rights reserved.
引用
收藏
页码:389 / 394
页数:6
相关论文
共 27 条
[1]   Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J].
Chan, KA ;
Andrade, SE ;
Boles, M ;
Buist, DSM ;
Chase, GA ;
Donahue, JG ;
Goodman, MJ ;
Gurwitz, JH ;
LaCroix, AZ ;
Platt, R .
LANCET, 2000, 355 (9222) :2185-2188
[2]   Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation [J].
Ducy, P ;
Zhang, R ;
Geoffroy, V ;
Ridall, AL ;
Karsenty, G .
CELL, 1997, 89 (05) :747-754
[3]   Oral statins and increased bone-mineral density in postmenopausal women [J].
Edwards, CJ ;
Hart, DJ ;
Spector, TD .
LANCET, 2000, 355 (9222) :2218-2219
[4]   ML-236A, ML-236B, AND ML-236C, NEW INHIBITORS OF CHOLESTEROGENESIS PRODUCED BY PENICILLIUM CITRINUM [J].
ENDO, A ;
KURODA, M ;
TSUJITA, Y .
JOURNAL OF ANTIBIOTICS, 1976, 29 (12) :1346-1348
[5]   Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfal signaling pathway in a Ras-independent manner: Further involvement of mevalonate-pathway blockade for incadronate [J].
Fujita, T ;
Izumo, N ;
Fukuyama, R ;
Meguro, T ;
Yasutomi, C ;
Nakamuta, H ;
Koida, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 2001, 86 (01) :86-96
[6]   Phosphate stimulates differentiation and mineralization of the chondroprogenitor clone ATDC5 [J].
Fujita, T ;
Meguro, T ;
Izumo, N ;
Yasutomi, C ;
Fukuyama, R ;
Nakamuta, H ;
Koida, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 2001, 85 (03) :278-281
[7]   Phosphate provides an extracellular signal that drives nuclear export of Runx2/Cbfa1 in bone cells [J].
Fujita, T ;
Izumo, N ;
Fukuyama, R ;
Meguro, T ;
Nakamuta, H ;
Kohno, T ;
Koida, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 280 (01) :348-352
[8]   Statins and bone formation [J].
Garrett, IR ;
Gutierrez, G ;
Mundy, GR .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (08) :715-736
[9]   Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors [J].
Hamelin, BA ;
Turgeon, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (01) :26-37
[10]   Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation [J].
Hashimoto, H ;
Ogawa, N ;
Hagihara, N ;
Yamamoto, K ;
Imanishi, K ;
Nogi, H ;
Nishino, A ;
Fujita, T ;
Matsuda, T ;
Nagata, S ;
Baba, A .
MOLECULAR PHARMACOLOGY, 1997, 52 (01) :128-135